“Our proprietary intranasal platform has the potential to enhance drug delivery bioavailability. We believe that intranasal delivery has the potential to improve patient outcomes by providing a ...

Polyrizon (PLRZ) announced that it has signed a non-binding Letter of Intent with a biotech company focused on psychedelic-derived ...

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced its plans to explore utilizing Molecular Envelope Technology (MET) ...

The intranasal delivery method of Naloxone presents several benefits, such as ease of use and the elimination of the need for medical professionals during administration, making it more accessible ...

This agreement aims to leverage Polyrizon's proprietary platform to optimize the delivery of innovative psychedelic treatments for therapeutic use. This collaboration emphasizes the growing potential ...

This collaboration emphasizes the growing potential of intranasal drug delivery in the psychedelic medicine space, offering an innovative approach to enhancing bioavailability, efficacy ...

This collaboration aims to utilize Polyrizon's proprietary intranasal hydrogel technology to improve the delivery and effectiveness of psychedelic treatments, highlighting the potential of ...

In a recent publication in Cell, researchers from the National University of Singapore and collaborators have proposed using commensal bacteria in the nasal cavity as a delivery vector for precision ...

Global Nanotechnology Drug Delivery Market is valued at USD 85.5 Billion in 2022. Global Nanotechnology Drug Delivery Market ...

Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal ...